🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Whole Genome Sequencing in Breast Cancer

Recruitingn/aAges 19 Years - anyAllInocras Korea Inc.
NCT06334471 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
\[Prospective study\] Inclusion Criteria: * Patients who have consented to both the patient consent form and the consent for the use of human-derived materials. * Patients who are aged 19 years or older at the time of signing the consent form. * Patients capable of providing written consent to participate voluntarily in the study. * Patients eligible for tissue examination and surgical removal to facilitate sample collection. * Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer. Exclusion Criteria: * Patients who do not understand or refuse to consent in writing. * Patients for whom obtaining sufficient samples is challenging. * Patients who refuse genetic testing. \[Retrospective study\] Inclusion Criteria: * Patients histologically confirmed with breast cancer. * Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution. Exclusion Criteria: \- Patients for whom sufficient tissue for analysis is not adequately stored.
💊

What it tests

  • no intervention needed
📍

Where

1 site
Samsung Medical Center
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy